CA3244475A1 - THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE - Google Patents
THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USEInfo
- Publication number
- CA3244475A1 CA3244475A1 CA3244475A CA3244475A CA3244475A1 CA 3244475 A1 CA3244475 A1 CA 3244475A1 CA 3244475 A CA3244475 A CA 3244475A CA 3244475 A CA3244475 A CA 3244475A CA 3244475 A1 CA3244475 A1 CA 3244475A1
- Authority
- CA
- Canada
- Prior art keywords
- acetamide
- isopropyl
- triazin
- pyrrolo
- oxothieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22315036.8 | 2022-02-21 | ||
| EP22315036 | 2022-02-21 | ||
| PCT/EP2023/054138 WO2023156643A1 (en) | 2022-02-21 | 2023-02-20 | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244475A1 true CA3244475A1 (en) | 2023-08-24 |
Family
ID=81326677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244475A Pending CA3244475A1 (en) | 2022-02-21 | 2023-02-20 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250129091A1 (https=) |
| EP (1) | EP4482841A1 (https=) |
| JP (1) | JP2025506729A (https=) |
| KR (1) | KR20240151767A (https=) |
| CN (1) | CN118843632A (https=) |
| AU (1) | AU2023222186A1 (https=) |
| CA (1) | CA3244475A1 (https=) |
| CO (1) | CO2024010803A2 (https=) |
| IL (1) | IL314781A (https=) |
| MX (1) | MX2024010216A (https=) |
| WO (1) | WO2023156643A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116375728B (zh) * | 2021-12-31 | 2025-06-10 | 成都赜灵生物医药科技有限公司 | 噻吩吡咯并三嗪酮类化合物及其用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210038877A (ko) * | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| JP2023523418A (ja) * | 2020-04-23 | 2023-06-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３の阻害剤としての三環式化合物 |
-
2023
- 2023-02-20 JP JP2024549135A patent/JP2025506729A/ja active Pending
- 2023-02-20 IL IL314781A patent/IL314781A/en unknown
- 2023-02-20 CN CN202380021421.XA patent/CN118843632A/zh active Pending
- 2023-02-20 EP EP23705039.8A patent/EP4482841A1/en active Pending
- 2023-02-20 WO PCT/EP2023/054138 patent/WO2023156643A1/en not_active Ceased
- 2023-02-20 MX MX2024010216A patent/MX2024010216A/es unknown
- 2023-02-20 AU AU2023222186A patent/AU2023222186A1/en active Pending
- 2023-02-20 US US18/834,987 patent/US20250129091A1/en active Pending
- 2023-02-20 CA CA3244475A patent/CA3244475A1/en active Pending
- 2023-02-20 KR KR1020247027615A patent/KR20240151767A/ko active Pending
-
2024
- 2024-08-08 CO CONC2024/0010803A patent/CO2024010803A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314781A (en) | 2024-10-01 |
| KR20240151767A (ko) | 2024-10-18 |
| US20250129091A1 (en) | 2025-04-24 |
| JP2025506729A (ja) | 2025-03-13 |
| MX2024010216A (es) | 2024-09-02 |
| CO2024010803A2 (es) | 2024-08-20 |
| CN118843632A (zh) | 2024-10-25 |
| EP4482841A1 (en) | 2025-01-01 |
| WO2023156643A1 (en) | 2023-08-24 |
| AU2023222186A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023263450B2 (en) | Pyridazine compounds for inhibiting nlrp3 | |
| AU2020421426A1 (en) | RORγt inhibitor, preparation method thereof and use thereof | |
| MXPA05001434A (es) | Compuestos de dihidropirazolopiridina. | |
| CN109071418B (zh) | 氨基酸衍生物的前药 | |
| KR20250005125A (ko) | NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 | |
| JP7417594B2 (ja) | Ｔｒｋ阻害剤としてのイミダゾ［１，２－ｂ］ピリダジン | |
| CA3244475A1 (en) | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE | |
| CN116583285B (zh) | N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘 | |
| KR20210035225A (ko) | Trk 억제제로서 이미다조[1,2-b]피리다진 유도체 | |
| BR112020017121A2 (pt) | Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7h-pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus para tratamento de influenza | |
| CA3203129A1 (en) | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease | |
| EP4463450A1 (en) | Fused heteroaryl hydroxamates as sting agonists | |
| KR20250038236A (ko) | 코로나바이러스 감염 치료용 화합물 | |
| WO2025175247A1 (en) | Imidazo-pyrazine derivatives and their use in the treatment of neurologic disorders | |
| EA051595B1 (ru) | Соединения пиридазина для ингибирования nlrp3 | |
| WO2025155786A1 (en) | Bicyclic tyrosine kinase 2 inhibitors and uses thereof | |
| CA3251045A1 (en) | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS | |
| HK1260638B (zh) | 氨基酸衍生物的前药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240816 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240820 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240820 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240820 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250130 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250130 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260128 |